{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T12:39:21Z","timestamp":1785760761832,"version":"3.56.0"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.ctrv.2021.102220","type":"journal-article","created":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T22:44:27Z","timestamp":1620686667000},"page":"102220","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Coordination and optimization of FDG PET\/CT and COVID-19 vaccination; Lessons learned in the early stages of mass vaccination"],"prefix":"10.1016","volume":"98","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2891-6558","authenticated-orcid":false,"given":"Lacey J.","family":"McIntosh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5266-0364","authenticated-orcid":false,"given":"Max P.","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9996-2012","authenticated-orcid":false,"given":"Kriti","family":"Mittal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giles F.","family":"Whalen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venu G.","family":"Bathini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasneem","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn L.","family":"Edmiston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William V.","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan M.","family":"Gerber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2021.102220_b0005","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/s12149-011-0568-x","article-title":"Axillary lymph node accumulation on FDG-PET\/CT after influenza vaccination","volume":"26","author":"Shirone","year":"2012","journal-title":"Ann Nucl Med"},{"key":"10.1016\/j.ctrv.2021.102220_b0010","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1007\/s00259-011-1729-9","article-title":"Duration of 18F-FDG avidity in lymph nodes after pandemic H1N1v and seasonal influenza vaccination","volume":"38","author":"Thomassen","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ctrv.2021.102220_b0015","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s00330-010-1719-5","article-title":"FDG uptake in axillary lymph nodes after vaccination against pandemic (H1N1)","volume":"20","author":"Panagiotidis","year":"2010","journal-title":"Eur Radiol"},{"issue":"5","key":"10.1016\/j.ctrv.2021.102220_b0020","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/RLU.0000000000001603","article-title":"Lymph node activation by PET\/CT following vaccination with licensed vaccines for human papilloma viruses","volume":"42","author":"Coates","year":"2017","journal-title":"Clin Nucl Med"},{"issue":"10","key":"10.1016\/j.ctrv.2021.102220_b0025","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1097\/RLU.0b013e3182177322","article-title":"Incidence and intensity of F-18 FDG uptake after vaccination with H1N1 vaccine","volume":"36","author":"Burger","year":"2011","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.ctrv.2021.102220_b0030","doi-asserted-by":"crossref","unstructured":"Mingos M, Howard S, Giacalone N, Kozono D, Jacene H. Systemic Immune Response to Vaccination on FDG-PET\/CT. Nucl Med Mol Imaging. 2016 Dec;50(4):358\u201361. doi: 10.1007\/s13139-015-0385-6. Epub 2015 Dec 9. PMID: 27994693; PMCID: PMC5135690.","DOI":"10.1007\/s13139-015-0385-6"},{"key":"10.1016\/j.ctrv.2021.102220_b0035","unstructured":"Local reactions, systemic reactions, adverse events, and serious adverse events: Moderna COVID-19 vaccine. Centers for Disease Control and Prevention; [February 11, 2021]; Available from: https:\/\/www.cdc.gov\/vaccines\/covid-19\/info-by-product\/moderna\/reactogenicity.html."},{"key":"10.1016\/j.ctrv.2021.102220_b0040","unstructured":"Local reactions, systemic reactions, adverse events, and serious adverse events: Pfizer-BioNTech COVID-19 vaccine. Centers for Disease Control and Prevention; [February 13, 2021]; Available from: https:\/\/www.cdc.gov\/vaccines\/covid-19\/info-by-product\/pfizer\/reactogenicity.html."},{"key":"10.1016\/j.ctrv.2021.102220_b0045","doi-asserted-by":"crossref","unstructured":"Baden LR, El Sahly HM, Essink B, Kotloff J, Frey S, et al for the COVE Study Group. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021;384:403\u201316. doi: 10.1056\/NEJMoa2035389.","DOI":"10.1056\/NEJMoa2035389"},{"key":"10.1016\/j.ctrv.2021.102220_b0050","doi-asserted-by":"crossref","unstructured":"Edmonds CE, Zuckerman SP, Conant EF. Management of Unilateral Axillary Lymphadenopathy Detected on Breast MRI in the Era of Coronavirus Disease (COVID-19) Vaccination. AJR 2021 Feb 5 [published online]. Accepted manuscript. doi: 10.2214\/AJR.21.25604.","DOI":"10.2214\/AJR.21.25604"},{"key":"10.1016\/j.ctrv.2021.102220_b0055","doi-asserted-by":"crossref","unstructured":"McIntosh LJ, Bankier AA, Vijayaraghavan GR, Licho R, Rosen MP. COVID-19 vaccination-related uptake on FDG PET\/CT: An emerging dilemma and suggestions for management. AJR 2021 Accepted Feb 26 [in press]. https:\/\/doi.org\/10.2214\/AJR.21.25728.","DOI":"10.2214\/AJR.21.25728"},{"key":"10.1016\/j.ctrv.2021.102220_b0060","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.2020210030","article-title":"Imaging of COVID-19 Vaccination at FDG PET\/CT","author":"Eifer","year":"2021","journal-title":"Radiology"},{"key":"10.1016\/j.ctrv.2021.102220_b0070","unstructured":"COVID-19 vaccine FAQs for healthcare professionals. Centers for Disease Control and Prevention; [February 24, 2021]; Available from: https:\/\/www.cdc.gov\/vaccines\/covid-19\/hcp\/faq.html."},{"key":"10.1016\/j.ctrv.2021.102220_b0075","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines \u2014 a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ctrv.2021.102220_b0080","doi-asserted-by":"crossref","unstructured":"Eshet Y, Tau N, Alhoubani Y, Kanana N, Domachevsky L, Eifer M. Prevalence of Increased FDG PET\/CT Axillary Lymph Node Uptake Beyond 6 Weeks after mRNA COVID-19 Vaccination. Radiology 2021: Apr 27: 210886. doi: 10.1148\/radiol.2021210886. Online ahead of print.","DOI":"10.1148\/radiol.2021210886"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737221000682?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737221000682?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:25:40Z","timestamp":1759656340000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737221000682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":15,"alternative-id":["S0305737221000682"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2021.102220","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Coordination and optimization of FDG PET\/CT and COVID-19 vaccination; Lessons learned in the early stages of mass vaccination","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2021.102220","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102220"}}